Stock Ideas
New
Stocks
Funds
Screener
Sectors
Watchlists
VYGR

VYGR - Voyager Therapeutics Inc Stock Price, Fair Value and News

8.52USD-0.28 (-3.18%)Market Closed

Market Summary

VYGR
USD8.52-0.28
Market Closed
-3.18%

VYGR Alerts

  • Big fall in Revenue (Y/Y)
  • Big fall in earnings (Y/Y)
  • Losses in recent quarter

VYGR Stock Price

View Fullscreen

VYGR RSI Chart

VYGR Valuation

Market Cap

463.4M

Price/Earnings (Trailing)

-152.24

Price/Sales (Trailing)

3.08

EV/EBITDA

145.95

Price/Free Cashflow

56.29

VYGR Price/Sales (Trailing)

VYGR Profitability

EBT Margin

-1.55%

Return on Equity

-0.89%

Return on Assets

-0.65%

Free Cashflow Yield

1.78%

VYGR Fundamentals

VYGR Revenue

Revenue (TTM)

150.5M

Rev. Growth (Yr)

-87.03%

Rev. Growth (Qtr)

61.76%

VYGR Earnings

Earnings (TTM)

-3.0M

Earnings Growth (Yr)

-109.13%

Earnings Growth (Qtr)

-120.09%

Breaking Down VYGR Revenue

Last 7 days

1.2%

Last 30 days

-0.6%

Last 90 days

-8.2%

Trailing 12 Months

-35.3%

How does VYGR drawdown profile look like?

VYGR Financial Health

Current Ratio

5.64

VYGR Investor Care

Shares Dilution (1Y)

24.94%

Diluted EPS (TTM)

-0.14

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs
Net sales
YearQ1Q2Q3Q4
20240000
202368.3M95.7M123.1M150.5M
202238.3M39.2M40.0M40.9M
2021159.6M132.2M15.9M37.4M
2020117.3M99.9M197.3M171.1M
201911.9M55.4M73.7M104.4M
20189.6M11.0M12.0M7.6M
201710.9M8.3M6.2M10.1M
201619.6M18.4M16.8M14.2M
201500017.3M
GRUFITY'S FAIR VALUE MODEL

Stocks Marked 'Very Cheap' by Grufity's Fair Value Model Have Outperformed Russell 2000 Index

Small Caps and Mid Caps are mostly overlooked by investors as all the focus goes to Magnificent 7. These stocks that are not part of the beauty contest require a deeper look. However, all large cap stocks were once small caps. Grufity's Fair Value model opens up this unverse as it separates high-performing, rewarding stocks from low-performing risky stocks. <b>Russell 2000 stocks that were marked 'Very Cheap' by the model doubled in three years while the index was flat.</b>

PurpleZone


Returns of $10,000 invested in:

Very Cheap Stocks: $21,859
Russell 2000 Index: $10,334
Very Expensive Stocks: $8,224


Russell 2000 stocks considered 'Very Cheap' by the model greatly outperformed Russell 2000 index and the 'Very Expensive' bucket over past three years.

Russell 2000 Index
Very Expensive Stocks
Very Cheap Stocks
Try For Just $1.99

Tracking the Latest Insider Buys and Sells of Voyager Therapeutics Inc

Filter Transactions
Datesorted ascendingNameBuy/Sell$ ValueAvg. Price# SharesTitle
Apr 02, 2024
swartz robin
sold
-13,407
9.88
-1,357
chief operating officer
Apr 02, 2024
sandrock alfred
sold
-119,454
9.86
-12,115
president and ceo
Apr 01, 2024
ferguson toby
acquired
-
-
105,000
chief medical officer
Feb 21, 2024
carter todd alfred
sold
-25,136
7.47
-3,365
chief scientific officer
Feb 21, 2024
swartz robin
sold
-29,546
7.45
-3,966
chief operating officer
Feb 21, 2024
pfreundschuh peter p.
sold
-28,079
7.46
-3,764
chief financial officer
Feb 21, 2024
sandrock alfred
sold
-97,226
7.46
-13,033
president and ceo
Feb 20, 2024
carter todd alfred
sold
-4,623
7.68
-602
chief scientific officer
Feb 09, 2024
fahey sandell jacquelyn
acquired
-
-
31,000
chief legal officer
Feb 09, 2024
carter todd alfred
acquired
-
-
38,500
chief scientific officer

1–10 of 50

Which funds bought or sold VYGR recently?

View All Details
Datesorted ascendingFund NameType% Chg$ Change$ Held% Portfolio
May 24, 2024
FARALLON CAPITAL MANAGEMENT LLC
added
77.4
10,434,000
21,338,500
0.10%
May 21, 2024
China Universal Asset Management Co., Ltd.
added
104
53,861
96,861
0.01%
May 17, 2024
Ikarian Capital, LLC
reduced
-40.87
-897,654
1,683,780
0.18%
May 17, 2024
Plato Investment Management Ltd
new
-
38,348
38,348
-%
May 16, 2024
CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM
reduced
-24.31
-7,284
36,840
-%
May 16, 2024
JANE STREET GROUP, LLC
new
-
386,542
386,542
-%
May 16, 2024
Virtus Investment Advisers, Inc.
new
-
117,753
117,753
0.08%
May 15, 2024
Kestra Advisory Services, LLC
added
18.68
563,816
2,387,540
0.02%
May 15, 2024
BARCLAYS PLC
reduced
-10.86
-11,000
548,000
-%
May 15, 2024
ARMISTICE CAPITAL, LLC
added
10.29
7,744,480
43,496,300
0.58%

1–10 of 47

Are Funds Buying or Selling VYGR?

Are funds buying VYGR calls or puts?
Calls
Puts
No. of funds holding Calls - Puts
Net Call Options
No. of funds that own VYGR
No. of Funds

Unveiling Voyager Therapeutics Inc's Major ShareHolders

Date FiledName of FilerPercent of ClassNo. of SharesForm Type
Feb 14, 2024
armistice capital, llc
9.63%
4,236,000
SC 13G/A
Feb 14, 2024
third rock ventures iii, l.p.
0%
0
SC 13G/A
Feb 13, 2024
vanguard group inc
5.75%
2,529,668
SC 13G/A
Jan 29, 2024
blackrock inc.
6.0%
2,632,679
SC 13G
Feb 24, 2023
neurocrine biosciences inc
19.9%
8,575,316
SC 13D/A
Feb 14, 2023
armistice capital, llc
8.80%
3,396,000
SC 13G
Feb 14, 2023
third rock ventures iii, l.p.
14.1%
5,428,933
SC 13G/A
Feb 09, 2023
vanguard group inc
5.06%
1,955,172
SC 13G/A
Jan 13, 2023
ecor1 capital, llc
9.98%
3,851,507
SC 13G/A
Apr 26, 2022
ecor1 capital, llc
11.1%
4,276,507
SC 13G/A

Recent SEC filings of Voyager Therapeutics Inc

View All Filings
Date Filed Form Type Document
Jun 13, 2024
8-K
Current Report
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading
Jun 07, 2024
4
Insider Trading

Peers (Alternatives to Voyager Therapeutics Inc)

NameMkt Capsorted ascendingRevenuePrice %, 1MReturns, 1YP/EP/SRev 1-YrInc 1-Yr
LARGE-CAP
53.7B
6.8B
8.51% 7.74%
-8.99
7.84
-64.45% -224.75%
22.5B
216.3K
-0.77% 465779.94%
-2.5K
104.0K
- -8.13%
20.3B
2.0B
8.81% -20.73%
-61.09
10.13
75.20% 68.82%
15.9B
2.5B
3.83% -12.90%
77.15
6.41
13.74% 186.89%
13.9B
3.8B
8.85% -0.77%
18.71
3.7
8.58% 129.81%
MID-CAP
5.2B
107.9M
-7.07% 79.45%
-9.53
48.09
54.84% -28.31%
5.1B
524.1M
0.17% -53.14%
-12.21
9.72
394.93% 39.61%
3.5B
251.0M
-2.92% -12.90%
-11.81
13.95
73.58% -86.73%
3.2B
240.7M
3.27% -27.64%
-6.79
12.77
-1.03% -213.92%
2.5B
813.8M
-1.46% -38.91%
-1.4K
3.03
56.43% 98.83%
2.0B
996.6M
11.55% 78.54%
-5.07
2.03
-26.66% 65.49%
SMALL-CAP
1.8B
411.3M
-9.60% 21.75%
27.32
4.32
60.38% -34.49%
534.3M
881.7K
13.28% 545.16%
-15.83
481.06
-77.61% 33.36%
235.5M
4.2M
-30.45% 48.53%
-1.89
56.62
-66.30% 48.24%
22.1M
2.1M
36.17% 264.31%
-0.95
7.61
-13.45% 69.54%

Voyager Therapeutics Inc News

Latest updates
Markets Insider44 hours ago

Voyager Therapeutics Inc Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)
(In null)
Income Statement (Quarterly)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Revenue61.8%19,51612,0654,6144,853150,48095,78341,08636,74932,41128,0741,4821,3576,5016,537117,84328,68118,06732,67420,43346,0875,197
Operating Expenses-0.8%35,69935,99834,12130,27927,59623,01326,64420,07922,00822,37226,62829,94232,09030,26633,31637,66242,50046,44238,24036,89834,490
  S&GA Expenses-16.0%8,60710,2428,2588,2949,0288,4627,3077,5527,6598,3518,71410,4379,7448,2708,2778,23910,2069,8918,4638,3229,659
  R&D Expenses5.2%27,09225,75625,86321,98518,56814,55119,33712,52714,34914,02117,91419,50522,34621,99725,03929,42332,29436,55129,77728,57624,831
EBITDA Margin-98.4%0.01*0.92*0.29*0.69*1.12*-0.98*-1.61*-1.65*-1.68*-1.76*2.61*0.31*---------
Income Taxes-98.3%14.00822-17759.00704----------------
Earnings Before Taxes-119.8%-11,31657,217-26,078-22,149124,748-23,61017,624-19,087-21,319---------12,574-15,00611,153-27,170
EBT Margin-101.7%-0.02*0.89*0.27*0.66*1.07*-1.13*-1.78*-1.82*-1.86*-1.90*2.31*0.28*---------
Net Income-120.1%-11,33056,395-25,901-22,208124,044-23,62617,624-19,087-21,3195,709-25,137-30,120-21,649-15,92685,611-8,681-24,263-12,574-15,00611,153-27,170
Net Income Margin-102.3%-0.02*0.88*0.26*0.66*1.06*-1.13*-0.43*-1.53*-1.85*-1.90*-5.85*0.14*---------
Free Cashflow331.0%56,626-24,515-21,833-2,045123,056-13,177-16,484-19,72734,38810,848-21,369-22,944---------
Balance Sheet
(In Millions)
Balance Sheet
(In Millions)
(*) denotes actual numbers (not divided by Millions)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Assets33.7%470351295316336159182189224194185209238262270297323355376389411
  Current Assets28.0%409320262282303124147152171137126149176198216247272305328341365
    Cash Equivalents108.0%14369.0065.0024426810098.0080.0013211711312011810614914616587.0083.0081.00113
  Net PPE5.4%17.0016.0017.0017.0017.0018.0018.0019.0019.0022.0023.0024.0025.0025.0023.0020.0019.0018.0015.0014.0013.00
Liabilities12.0%12911511811711910010312914899.0097.0098.00102107104221243255268270311
  Current Liabilities12.5%73.0065.0062.0045.0020.0073.0073.0098.0010251.0027.0025.0025.0027.0042.0068.0073.0076.0080.0069.0059.00
Shareholder's Equity44.2%34123617619921759.0080.0060.0076.0095.0087.0011113615416677.0080.00100108118101
  Retained Earnings-4.3%-272-261-317-291-269-393-369-387-368-347-352-327-297-275-259-345-336-312-300-285-296
  Additional Paid-In Capital23.4%614498494491487453450448445442440438434430426422416412408403397
Shares Outstanding23.3%54.0044.0044.0044.0041.0039.0038.0038.0038.0038.0038.0038.00---------
Float----489---114---103---292---686-
Cashflow (Last 12 Months)
(In Thousands)
Cashflow (Quarterly)
(In Thousands)
(*) denotes actual numbers (not divided by Thousands)
Description(%) Q/Q2024Q12023Q42023Q32023Q22023Q12022Q42022Q32022Q22022Q12021Q42021Q32021Q22021Q12020Q42020Q32020Q22020Q12019Q42019Q32019Q22019Q1
Cashflow From Operations347.3%58,767-23,760-21,051-835123,565-12,244-16,206-18,48534,42611,195-20,709-22,717-21,294-21,977-24,740-21,201-28,798-23,360-21,579-31,557125,162
  Share Based Compensation17.3%3,5733,0452,8782,6722,5582,3462,1892,4902,3191,6542,0783,9913,6013,5023,5323,8604,0403,5203,3495,2533,518
Cashflow From Investing-458.0%-96,06526,833-158,304-24,66314,49114,06734,722-36,130-19,998-5,46414,34022,40534,625-21,51627,356-1,838108,99326,46222,610-2,888-136,661
Cashflow From Financing24433.9%112,8564603311,54831,30627615.0080712.00227-35728.004865102,13334.003001,7241,06977,901
Get Full Access to Grufity – and Unlimited Downloads
Gain full access to fair value, watchlists, stock screener, unlimited page visits, and additional features by joining as a member today for just $1.99.
Try For Just $1.99

VYGR Income Statement

2024-03-31
Condensed Consolidated Statements of Operations and Comprehensive (Loss) Income - USD ($)
$ in Thousands
3 Months Ended
Mar. 31, 2024
Mar. 31, 2023
Condensed Consolidated Statements of Operations and Comprehensive Income (Loss)  
Collaboration revenue$ 19,516$ 150,480
Operating expenses:  
Research and development27,09218,568
General and administrative8,6079,028
Total operating expenses35,69927,596
Operating (loss) income(16,183)122,884
Other income:  
Interest income4,8671,864
Total other income4,8671,864
(Loss) income before income taxes(11,316)124,748
Income tax provision14704
Net (loss) income(11,330)124,044
Other comprehensive (loss) income:  
Net unrealized (loss) gain on available-for-sale securities(458)87
Total other comprehensive (loss) income(458)87
Comprehensive (loss) income$ (11,788)$ 124,131
Net (loss) income per share, basic$ (0.20)$ 3.05
Net (loss) income per share, diluted$ (0.20)$ 2.94
Weighted-average common shares outstanding, basic57,117,04640,632,087
Weighted-average common shares outstanding, diluted57,117,04642,161,326

VYGR Balance Sheet

2024-03-31
Condensed Consolidated Balance Sheets - USD ($)
$ in Thousands
Mar. 31, 2024
Dec. 31, 2023
Current assets:  
Cash and cash equivalents$ 143,078$ 68,802
Marketable securities, current256,490162,073
Accounts receivable83780,150
Related party collaboration receivable2,6203,341
Prepaid expenses and other current assets6,1125,318
Total current assets409,137319,684
Property and equipment, net17,38116,494
Deposits and other non-current assets2,8901,593
Marketable securities, non-current980 
Operating lease, right-of-use assets39,20413,510
Total assets469,592351,281
Current liabilities:  
Accounts payable7,5791,604
Accrued expenses7,59516,823
Other current liabilities5,9403,200
Deferred revenue, current51,43942,881
Total current liabilities72,55364,508
Deferred revenue, non-current13,15732,359
Other non-current liabilities42,99618,094
Total liabilities128,706114,961
Commitments and contingencies (see note 7)
Stockholders' equity:  
Preferred stock, $0.001 par value: 5,000,000 shares authorized at March 31, 2024 and December 31, 2023; no shares issued and outstanding at March 31, 2024 and December 31, 2023
Common stock, $0.001 par value: 120,000,000 shares authorized at March 31, 2024 and December 31, 2023; 54,318,133 and 44,038,333 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively5444
Additional paid-in capital613,850497,506
Accumulated other comprehensive loss(506)(48)
Accumulated deficit(272,512)(261,182)
Total stockholders' equity340,886236,320
Total liabilities and stockholders' equity$ 469,592$ 351,281
VYGR
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of Alzheimer's disease. It also develops VY-FXN01 to treat Friedreich's ataxia; superoxide dismutase 1 gene silencing program for the treatment of amyotrophic lateral sclerosis; and GBA1 gene replacement program to treat Parkinson's disease. In addition, the company develops research program for the treatment of Huntington's disease. It has collaboration and license agreements with Neurocrine Biosciences, Inc.; Pfizer Inc.; and Novartis Pharma, A.G. for the research, development, and commercialization of adeno-associated virus gene therapy products. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Cambridge, Massachusetts.
 CEO
 WEBSITEvoyagertherapeutics.com
 INDUSTRYBiotechnology
 EMPLOYEES125

Voyager Therapeutics Inc Frequently Asked Questions


What is the ticker symbol for Voyager Therapeutics Inc? What does VYGR stand for in stocks?

VYGR is the stock ticker symbol of Voyager Therapeutics Inc. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Voyager Therapeutics Inc (VYGR)?

As of Fri Jun 14 2024, market cap of Voyager Therapeutics Inc is 463.43 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of VYGR stock?

You can check VYGR's fair value in chart for subscribers.

What is the fair value of VYGR stock?

You can check VYGR's fair value in chart for subscribers. The fair value of Voyager Therapeutics Inc is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Voyager Therapeutics Inc is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for VYGR so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Voyager Therapeutics Inc a good stock to buy?

The fair value guage provides a quick view whether VYGR is over valued or under valued. Whether Voyager Therapeutics Inc is cheap or expensive depends on the assumptions which impact Voyager Therapeutics Inc's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for VYGR.

What is Voyager Therapeutics Inc's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Fri Jun 14 2024, VYGR's PE ratio (Price to Earnings) is -152.24 and Price to Sales (PS) ratio is 3.08. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. VYGR PE ratio will change depending on the future growth rate expectations of investors.